Who are IL-23 Therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ustekinumab Injection, Anti-IL12/23 or anti-IL23 - Ustekinumab, Ustekinumab (UST), Tildrakizumab Prefilled Syringe, Anti-IL12/23 or anti-IL23 - Risankizumab, Mirikizumab - SC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/il-23-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

IL-23 Therapy — Competitive Intelligence Brief

IL-23 Therapy (IL-23 Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IL-23 inhibitor. Area: Immunology.

phase 3 IL-23 inhibitor IL-23 (interleukin-23) Immunology Biologic Live · refreshed every 30 min

Target snapshot

IL-23 Therapy (IL-23 Therapy) — Weill Medical College of Cornell University. IL-23 therapy inhibits the IL-23 signaling pathway to reduce pathogenic T-cell responses and inflammatory cytokine production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IL-23 Therapy TARGET	IL-23 Therapy	Weill Medical College of Cornell University	phase 3	IL-23 inhibitor	IL-23 (interleukin-23)
Ustekinumab Injection	Ustekinumab Injection	National Medical Research Center for Children's Health, Russian Federation	marketed	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12/IL-23 p40 subunit
Anti-IL12/23 or anti-IL23 - Ustekinumab	Anti-IL12/23 or anti-IL23 - Ustekinumab	University of Calgary	marketed	Monoclonal antibody; IL-12/IL-23 inhibitor	IL-12 p40 subunit (shared with IL-23)
Ustekinumab (UST)	Ustekinumab (UST)	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	IL-12/IL-23 inhibitor monoclonal antibody	IL-12 p40 / IL-23 p40 subunit
Tildrakizumab Prefilled Syringe	Tildrakizumab Prefilled Syringe	Brigham and Women's Hospital	marketed	IL-23 inhibitor (monoclonal antibody)	IL-23 (interleukin-23), p19 subunit
Anti-IL12/23 or anti-IL23 - Risankizumab	Anti-IL12/23 or anti-IL23 - Risankizumab	University of Calgary	marketed	IL-23 inhibitor monoclonal antibody	IL-23 (p19 subunit)
Mirikizumab - SC	Mirikizumab - SC	Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives	marketed	IL-23 inhibitor monoclonal antibody	IL-23 p19 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IL-23 inhibitor class)

AbbVie · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IL-23 Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/il-23-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab